Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer (Q41060508)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1 reference

Europe PubMed Central

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

B Fulton

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

C M Spencer

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

publication date

1 June 1996

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1075-1092

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Breast cancer (1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical evaluation of docetaxel (Taxotere).

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in chemotherapy for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere) in combination: a step forward.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Taxol-induced polymerization of purified tubulin. Mechanism of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABC of breast diseases. Breast cancer--epidemiology, risk factors and genetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of Taxotere (docetaxel).

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving treatment for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic Therapy of Advanced Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The taxoids: paclitaxel and docetaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral neurotoxicity induced by docetaxel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Taxotere on murine and human tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of Taxotere: five-day schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8736622

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199651060-00011

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41060508&oldid=2204233446"